Prevalence of obstructive sleep apnoea in metabolic syndrome

A. P. Dubey¹, Ashok K. Rajput², Virender Suhag³*, Durgesh Sharma⁴, Ajay Kandpal⁴, Roshlin Keisham⁴

¹Department of Medicine and Medical Oncology, Army Hospital (R and R), Delhi Cantt-110010, New Delhi, India
²Department of Medicine, Venkateswara Hospital, Dwarka, New Delhi-110075, India
³Department of Radiation Oncology, Army Hospital (R and R), Delhi Cantt-110010, New Delhi, India
⁴Department of Medicine, Army Hospital (R and R), Delhi Cantt-110010, New Delhi, India

Received: 23 January 2017
Accepted: 22 February 2017

*Correspondence: Dr. Virender Suhag, E-mail: virendersuhag@gmail.com

ABSTRACT

Background: The prevalence of both OSA and metabolic syndrome is increasing worldwide, in part linked to the epidemic of obesity. Beyond their epidemiologic relationship, growing evidence suggests that OSA may be causally related to metabolic syndrome. We are only beginning to understand the potential mechanisms underlying the OSA-metabolic syndrome interaction. Objectives were to study the clinical prevalence of obstructive sleep apnoea in metabolic syndrome; and to find risk factors associated with obstructive sleep apnoea (OSA).

Methods: 50 patients attending various OPDs of a tertiary care research and referral hospital and found to have metabolic syndrome on the basis of NCEP criteria were selected. These patients were subjected to overnight polysomnography. Parameters such as apnea-hypopnoea index (AHI), respiratory efforts related arousals (RERA), minimum SpO2, pulse rate, blood pressure, and ECG were monitored throughout the study.

Results: Central obesity was found in 34 patients, xanthelasmas in 12 patients and xanthomas in 08 patients. Pitting type of pedal oedema was noted in 14 patients. Epworth sleepiness score (ESS) was calculated in all the patients by interviewing them before the polysomnography. Most of the patients have ESS Score more than 11.03 out of 50 patients were found to have AHI<5.20 patients were found to have moderate AHI (AHI 15-30) whereas 22 were found to have severe AHI.

Conclusions: Polysomnography provides a valuable tool to access non symptomatic sleep disordered breathing at an early stage in patients with metabolic syndrome.

Keywords: AHI, Metabolic syndrome, Obstructive sleep apnoea, Polysomnography

INTRODUCTION

Sleep disorders are common among the general population.¹,² Sleep related breathing disorders (SRBD) can impair academic and occupational performance, cause work-related and road accidents, and disturb mood and social adjustment. Private life and relationships may be adversely affected by the patient’s SRBD. In addition, sleep-related breathing disorders may lead to or exacerbate serious medical, neurological and psychiatric problems.³ Apnea is defined as reduction in airflow greater than or equal to 90% of baseline, recorded by oronasal thermistors or nasal pressure cannulas; duration ≥10 sec; and aforementioned reduction in airflow at least 90% of the event. The apnea-hypopnea index (AHI) refers to the average number of apneas and hypopneas per hour of sleep. AHI is used to describe the number of complete and partial obstructive events per hour of sleep.
Obstructive sleep apnea (OSA) or obstructive sleep apnea syndrome is the most common type of sleep apnea and is caused by obstruction of the upper airway. It is characterized by repetitive episodes of partial or complete obstruction of the upper airway during sleep, ultimately leading to increased respiratory effort, oxyhemoglobin desaturation, sleep fragmentation, and excessive daytime sleepiness. These pauses in breathing, called apneas (literally, "without breath"), typically last 20 to 40 seconds.\(^5\)\(^6\)

The primary cause of OSA is inspiratory collapse of the pharyngeal airway. This portion of the airway has little rigid support and is largely dependent on neuromuscular control to maintain patency.\(^6\) Patients with OSA have an anatomically small pharyngeal airway, which in adults is primarily due to obesity and is improved by weight loss and in children is most commonly due to enlarged tonsils and adenoids.\(^7\) While awake, this leads to greater airway resistance that activates mechanoreceptors to trigger reflex pharyngeal dilator muscle activity, thus maintaining airway patency.\(^8\) During sleep, dilator muscle activity is diminished, leading to pharyngeal narrowing and intermittent collapse of the upper airway. This can lead to a combination of hypopneas, or reduction in airflow associated with a fall in oxygen saturation, or apneas, or complete cessation of airflow.\(^9\) OSA severity is usually determined as follows: AHI 5-15 indicates mild, 15-30 moderate and over 30 severe OSAS. The oxygen saturation index (ODI 4%) describes the number of at least 4% drops in blood oxygen levels per hour of sleep. Obstructive sleep apnoea (OSA) is widely prevalent disorder particularly amongst middle-aged, obese men, although it’s existence in women as well as in lean individuals is increasingly recognized. Obstructive sleep apnea is a highly prevalent but underrecognized clinical problem. In an urban setting in northern India, the prevalence of obstructive sleep apnea and the obstructive sleep apnea syndrome is reported to be 13.7% and 3.8%, respectively.\(^10\)

The metabolic syndrome, a cluster of cardiovascular risk factors, is associated with obstructive sleep apnea.\(^7\) Its prevalence varies from 74 to 85% among patients with obstructive sleep apnea and from 37 to 41% among patients with nonobstructive sleep apnea.\(^11\) Obstructive sleep apnea has been shown to be an independent risk factor for hypertension and insulin resistance.\(^12,13\)

Patients with OSA have abnormalities in each of the “core” components of the metabolic syndrome- high blood pressure, high fasting glucose, increased waist circumference, low HDL cholesterol, and high triglycerides as well as in many of its other features, including sympathetic activation, endothelial dysfunction, systemic inflammation, hypercoagulability, and insulin resistance. It has even been suggested that the metabolic syndrome (“Syndrome X”) should encompass OSA (“Syndrome Z”).\(^14\)

Metabolic syndrome (MS) is a combination of medical disorders that, when occurring together, increase the risk of developing cardiovascular disease and diabetes. This syndrome includes the clustering of abdominal obesity, insulin resistance, dyslipidemia, and elevated blood pressure. Additionally, it is associated with an immense number of other comorbidities.\(^8,15\) As the term syndrome implies, a single specific causative etiology to MetS is not clear. Nevertheless, abdominal adiposity and insulin resistance appear to be at the core of the pathophysiology of MetS and its individual components. The most accepted and unifying hypothesis to describe the pathophysiology of metabolic syndrome is insulin resistance. Although the incidence of metabolic syndrome in India is on the rise, there is paucity of Indian data on its correlation with obstructive sleep apnoea.\(^15\) This study was primarily designed to study the clinical prevalence of in metabolic syndrome; and to find risk factors associated with obstructive sleep apnoea (OSA).

**METHODS**

**Setting**

This study was undertaken at a tertiary care, research-oriented, super-specialty Hospital of Indian army. This centre has got high volume of patients with likely metabolic syndrome and has got all the facilities for adequate work-up and management of such cases as per standard guidelines.

**Study design**

It was a prospective observational and interventional study. Before conduct of study, the study design was exhaustively discussed in scientific committee and ethical committee of the institute and due permissions obtained. The objectives of the study and the criteria for patient selection were well-defined. The study period ranged from May 2010 to April 2013. 50 patients attending various OPDs at Army Hospital (R and R), Delhi Cantonment, New Delhi, India and found to have metabolic syndrome on the basis of NCEP criteria were selected for the study. These patients were subjected to overnight polysomnography and parameters such as apnea index (AHI), RERA, minimum SpO2, pulse rate, blood pressure, and ECG were monitored throughout the study.

**Subjects**

All patients who were found to have metabolic syndrome on the basis of NCEP criteria in the study period were included.

**Study criteria**

The individual must fulfil criterion A, B and D, or C and D for obstructive sleep apnea-hypopnea syndrome (OSAHS).
A. At least one of the following:

- Sleepiness, hypersomnolence, exhaustion or insomnia
- Arousals with feeling of asphyxiations/ suffocation.
- Snoring, breathing pauses witnessed by sleep partner.

B. Polysomnography findings:

- Apnea, hypopnea or RERAs ≥5 per hour of sleep.
- Recording of respiratory effort during part of or the whole event.

C. Polysomnographic findings:

- Apnea, hypopnea or RERAs ≥ 15 per hour of sleep.
- Recording of respiratory effort during part of or the whole event.

D. The disorder cannot be attributed to other conditions, use of medicines or other substances.

RESULTS

Study was carried on 50 patients of metabolic syndrome as per National Cholesterol Education Programme Adult Treatment Panel (NCEP ATP III) who were subjected to overnight polysomnography. There were 42 males and 08 females.

The age of the patients in the study ranged from 29 to 74 years with a mean age of 54.8±11.7 years. Age of male patients ranged from 38 to 74 years with mean age of 55.86±11.60 years, whereas age of female patients ranged from 29 to 65 years with mean age of 49.25±11.71 years. Mean body mass index of the study group was 30.23±1.9kg/m². In males BMI ranged from 26.5 to 35.3kg/m² with a mean of 30.36±1.85kg/m². In females mean BMI was 29.55±1.85kg/m².

Table 1: Correlation of BMI with AHI.

| BMI_g | AHI_g | Normal | Mild | Moderate | Severe | Total |
|-------|-------|--------|------|----------|--------|-------|
| BMI ≥25 to 29.9 | 0 | 3 | 8 | 4 | 15 |
| BMI ≥30 | 2 | 2 | 13 | 18 | 35 |
| Total | 2 | 5 | 21 | 22 | 50 |
| Pearson Chi-square | 5.119 | p-value | 0.163 |

General physical examination revealed central obesity in 34 patients. Xanthelasmas were found in 12 patients, while 8 patients were having Xanthomatis. Pitting type of pedal oedema was noted in 14 patients. Epworth sleepiness score (ESS) was calculated in all the patients by interviewing them before the Polysomnography. It was found that most of the patients have ESS score more than 11.

Out of 50 patients three (6%) had normal AHI (AHI<5). Five (10%) had mild OSA with AHI between 5 and 15. Twenty (40%) patients had moderate OSA (AHI 15 to 30). Twenty-two (44%) people had severe OSA (AHI>30). The majority of severe OSA patients (64%) were in the middle-aged group.

Table 2: Mean values of different variables according to AHI group.

| AHI_g | Normal | Mild | Moderate | Severe | Total |
|-------|--------|------|----------|--------|-------|
| BMI (kg/m²) | 31.12 | 29.45 | 29.81 | 30.73 | 30.23 |
| Waist Circumference(cm) | 104.5 | 102.75 | 98.81 | 101.8 | 100.75 |
| Hip circumference (cm) | 112 | 106.4 | 102.62 | 103.77 | 103.88 |
| WHR | 0.93278 | 0.96639 | 0.96327 | 0.98199 | 0.9706 |
| Systolic | 142 | 145.2 | 147.81 | 153.18 | 149.68 |
| Diastolic | 88 | 91.2 | 93.9 | 97.82 | 95.12 |
| Fasting plasma glucose(mg/dl) | 135 | 115.4 | 110.9 | 143.68 | 126.74 |
| TG | 177.5 | 172.6 | 180.86 | 214.91 | 194.88 |
| CHOL | 170 | 194.6 | 184.52 | 214.45 | 198.12 |
| HDL | 65 | 55.2 | 56.67 | 57.86 | 57.38 |

The mean BMI of the series of 30.23kg/m². Sixty eight percent (68%) of patients were obese whereas 32% patients were pre-obese (overweight) and non-obese. OSA was found in pre-obese and even non-obese but severity of OSA was more in obese patients. The correlation of BMI with AHI is shown in Table 1. The Mean values of different variables according to AHI group is shown in Table 2.
Thirty-three (66%) patients were having fasting plasma glucose in diabetic range. Out of 33 patients, 21 (64%) had severe OSA. Significant correlation was found between uncontrolled plasma glucose and severity of OSA. Mean systolic blood pressure (SBP) of the series was 149.7 mm of Hg. Out of 50 patients, 32 (64%) patients were hypertensives. None of the hypertensives had normal AHI whereas 64% of hypertensives had severe OSA. Forty-nine (98%) patients were dyslipidemics. Only 4% of them had normal AHI. Thirty eight percent (38%) had moderate OSA whereas 46% had severe OSA.

**DISCUSSION**

This work explores the association between MS and OSA in otherwise-healthy Caucasian male. So far, various studies have focused on detecting MS in OSA patients and showing that MS is more frequent in such patients than in the general population. The new aspect of this study is attempting to examine the reverse association.

There is adequate scientific evidence to suggest that obstructive sleep apnoea is a very prevalent disorder amongst middle aged, obese men, though its existence in women is also increasingly recognized. Despite the extensive literature on the role of anatomical abnormalities in pathogenesis of sleep apnoea, the large majority of sleep apnoeics do not demonstrate structural abnormalities and vice versa.

In present study conducted on 50 diagnosed patients, who fulfilled the criteria for metabolic syndrome, a very high prevalence of sleep disordered breathing was observed. Although studies have proven OSA as an independent risk for hypertension, present study demonstrates that severity of OSA correlates with severity of hypertension. Severe hypertension was associated with higher AHI as compared to mild and moderate hypertension. Presently there are a couple of sets of defining criteria for metabolic syndrome set out by two different sources- the International Diabetes Federation and the revised National Cholesterol Education Program (NCEP). These are very similar and they identify individuals with a given set of symptoms as having metabolic syndrome. In the study conducted NCEP criteria has been used to ascertain metabolic syndrome among the subjects.

The US National Cholesterol Education Program Adult Treatment Panel III (2001) requires at least three of the following: central obesity: waist circumference ≥102 cm or 40 inches (male), ≥88 cm or 36 inches (female); dyslipidemia: TG≥1.7 mmol/L (150 mg/dl); dyslipidemia: HDL-C<40 mg/dl (male), <50 mg/dl (female); blood pressure ≥130/85 mmHg; and fasting plasma glucose ≥6.1 mmol/L (110 mg/dl).

The present reference or “gold” standard for evaluation of sleep and sleep-related breathing is the in-laboratory polysomnogram (PSG), which was established through evidence-based reviews conducted by the American Academy of Sleep Medicine (AASM). This method has been proven to be accurate with a low failure rate because the study methods are more likely to be present in subjects with OSA.

In present study, 33 patients (66%) were having fasting plasma glucose in diabetic range, out of which 64% had severe OSA; whereas 32 (64%) patients were hypertensives, out of which 64% of hypertensives had severe OSA. Obstructive sleep apnoea (OSA) is associated with increased cardiovascular morbidity and mortality.

Although it was previously assumed that this was due to its relationship with obesity, recent data suggest that OSA is independently associated with the cardiovascular risk factors that comprise metabolic syndrome, including hypertension, insulin resistance, impaired glucose tolerance, and dyslipidaemia. Coughlin SR and colleagues demonstrated that OSA was independently associated with increased systolic and diastolic blood pressure, higher fasting insulin and triglyceride concentrations, decreased HDL cholesterol, increased cholesterol: HDL ratio, and a trend towards higher HOMA values. In this study, metabolic syndrome was 9.1 times more likely to be present in subjects with OSA.

Gruber A and colleagues demonstrated that OSA is associated with MS independent of obesity predominantly due to increased triglyceride, glucose and Epworth score values but not insulin resistance (IR) or microalbuminuria status. This observation suggests an alternative pathogenic factor mediating the increased cardiovascular risk in patients with OSA and MS, other than that due to IR.

**CONCLUSION**

Polysomnography provides a valuable tool to access nonsymptomatic sleep disordered breathing at an early stage in patients with metabolic syndrome. In view of rising incidence of metabolic syndrome worldwide, the various diagnostic tools to establish and manage OSA must be exhaustively used. More studies need to be undertaken in Indian setup to establish guidelines for management of such cases.

**Funding:** No funding sources

**Conflict of interest:** None declared

**Ethical approval:** The study was approved by the institutional ethics committee
REFERENCES

1. Peppard PE, Young T, Barnet JH, Palta M, Hagen EW, Hla KM. Increased prevalence of sleep-disordered breathing in adults. Am J Epidemiol. 2013;177(9):1006-14.

2. Young T, Peppard PE, Gottlieb DJ. Epidemiology of obstructive sleep apnea: a population health perspective. Am J Respir Crit Care Med. 2002;165(9):1217-39.

3. Goldbart AD. Sleep medicine. Curr Opin Pediatr. 2015;27(3):329-33.

4. Young T, Jawaheri S. Cardiovascular disorders: systemic and pulmonary hypertension in obstructive sleep apnea. In: Kryger MH, Roth T, Dement WC, eds. Principles and practice of sleep medicine. 4. ed. Philadelphia, PA: Elsevier/Saunders; 2005:1192-1202.

5. AASM (2001). The International Classification of Sleep Disorders, Revised. Westchester, Illinois: American Academy of Sleep Medicine. 2001:52-8. Retrieved 2010-09-11.

6. Somers VK, White DP. Amin R. Sleep apnea and cardiovascular disease: An American Heart Association/American College of Cardiology Foundation Scientific Statement From the American Heart Association Council for High Blood Pressure Research Professional Education Committee, Council on Clinical Cardiology, Stroke Council, and Council on Cardiovascular Nursing. In Collaboration With the National Heart, Lung, and Blood Institute National Center on Sleep Disorders Research (National Institutes of Health). J Am Coll Cardiol. 2008;52:686-717.

7. Schwab RJ. Pasiecznik M. Pierson R. Identification of upper airway anatomic risk factors for obstructive sleep apnea with volumetric magnetic resonance imaging. Am J Respir Crit Care Med. 2003;168:522-30.

8. Fogel RB, Malhotra A, Pillar G. Genioglossal activation in patients with obstructive sleep apnea versus control subjects. Mechanisms of muscle control. Am J Respir Crit Care Med. 2001;164:2025-30.

9. Calvin AD, Albuquerque FN, Jimenez FL, Somers VK. Obstructive sleep apnea, inflammation, and the metabolic syndrome. Metab Syndr Relat Disord. 2009;7(4):271-7.

10. Sharma SK, Kumpawat S, Banga A, Goel A. Prevalence and risk factors of obstructive sleep apnea syndrome in a population of Delhi, India. Chest. 2006;130:149-56.

11. Sharma SK, Reddy EV, Sharma A. Prevalence and risk factors of syndrome Z in urban Indians. Sleep Med. 2010;11:562-8.

12. Nieto FJ, Young TB, Lind BK. Association of sleep-disordered breathing, sleep apnea, and hypertension in a large community-based study: Sleep Heart Health Study. JAMA. 2000;283:1829-36.

13. Ip MS, Lam B, Ng MM, Lam WK, Tsang KW, Lam KS. Obstructive sleep apnea is independently associated with insulin resistance. Am J Respir Crit Care Med. 2002;165:670-6.

14. Sharma SK, Sreenivas V. Are metabolic syndrome, obstructive sleep apnoea and syndrome Z sequential? A hypothesis. Indian J Med Res. 2010;131:455-8.

15. Sreedharan SE, Agrawal P, Rajith RS, Nair S, Sarma SP, Radhakrishnan A. Clinical and polysomnographic predictors of severe obstructive sleep apnea in the South Indian population. Ann Indian Acad Neurol. 2016;19(2):216-20.

16. Vgontzas AN, Kales A. Sleep and its disorders. Annu Rev Med. 1999;50:387-400.

17. Young T, Palta M, Dempsey J, Skatrud J, Weber S, Badr S. The occurrence of sleep-disordered breathing among middle-age adults. N Engl J Med. 1993;328:1230-3.

18. Bassiri AG, Guilleminault C. Clinical features and evaluation of obstructive sleep apnea-hypopnea syndrome. In: Kryger MH, Roth T, Dement WC, eds. Sleep Medicine. Philadelphia: W.B. Saunders, 2000;869-878.

19. Bixler EO, Vgontzas AN, Ten Have T, Tyson K, Kales A. Effects of age on sleep apnea in men: I. Prevalence and severity. Am J Respir Crit Care Med. 1998;157:144-8.

20. Zhang W, Si LY. Obstructive sleep apnea syndrome (OSAS) and hypertension: pathogenic mechanisms and possible therapeutic approaches. Upsala J Med Sci. 2012;117(4):370-82.

21. Phillips CL, Cistulli PA. Obstructive sleep apnea and hypertension: epidemiology, mechanisms and treatment effects. Minerva Med. 2006;97(4):299-312.

22. Parikh RM, Mohan V. Changing definitions of metabolic syndrome. Indian J Endocrinol Metab. 2012;16(1):7-12.

23. Hwu CM, Hsiung CA, Wu KD, Lee WJ, Shih KC, Grove J, et al. Diagnosis of insulin resistance in hypertensive patients by the metabolic syndrome: AHA vs. IDF definitions. Int J Clin Pract. 2008;62:1441-6.

24. Deepa M, Farooq S, Datta M, Deepa R, Mohan V. Prevalence of metabolic syndrome using WHO, ATPIII and IDF definitions in Asian Indians: the Chennai Urban Rural Epidemiology Study (CURES-34). Dia Metab Res Rev. 2007;23:127-34.

25. National Institutes of Health: Third Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Executive Summary. Bethesda, MD, National Institutes of Health, National Heart, Lung and Blood Institute. 2001 (NIH publ. no. 01-3670)

26. Kushida CA, Littner MR, Morgenthaler T, Alessi CA, Bailey D, Coleman J, et al. Practice parameters for the indications for polysomnography and related

International Journal of Advances in Medicine | May-June 2017 | Vol 4 | Issue 3 | Page 726
procedures: an update for 2005. Sleep. 2005;28(4):499-521.

27. Collop NA, Anderson WM, Boehlecbe B, Claman D, Goldberg R, Gottlieb DJ, et al. Clinical guidelines for the use of unattended portable monitors in the diagnosis of obstructive sleep apnea in adult patients. Portable Monitoring Task Force of the American Academy of Sleep Medicine. Journal of clinical sleep medicine: JCSM: official publication of the American Academy of Sleep Medicine. 2007;3(7):737-47.

28. Coughlin SR, Mawdsley L, Mugarza JA, Calverley PM, Wilding JP. Obstructive sleep apnoea is independently associated with an increased prevalence of metabolic syndrome. Eur Heart J. 2004;25(9):735-41.

29. Gruber A, Horwood F, Sithole J, Ali NJ, Idris I. Obstructive sleep apnoea is independently associated with the metabolic syndrome but not insulin resistance state. Cardiovasc Diabetol. 2006;5:22.

Cite this article as: Dubey AP, Rajput AK, Suhag V, Sharma D, Kandpal A, Keisham R. Prevalence of obstructive sleep apnoea in metabolic syndrome. Int J Adv Med 2017;4:722-7.